Small for gestational age (SGA): endocrine and metabolic consequences and effects of growth hormone treatment.

Plain-language guide to PMID 15134308 (2004): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 79 children.

Key Facts

PMID: 15134308
Journal: Journal of pediatric endocrinology & metabolism : JPEM
Year: 2004
Study type: Randomized Controlled Trial
Authors: Hokken-Koelega AC et al. (5 authors)

What This Study Did, in Plain Language

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

For that reason concern has been expressed regarding possible detrimental effects of GH therapy in children born SGA.

Inclusion criteria were: 1) birth length SDS below -1.88, 2) age 3-11 years in boys and 3-9 years in girls, 3) height SDS < -1.88, 4) no spontaneous catch-up growth, and 5) an uncomplicated neonatal period.

Who Took Part

The abstract describes 79 children taking part.

The age groups tagged for this paper are young children and children, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and multicenter study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

What Was Measured

GH therapy induced considerably higher fasting and glucose-stimulated insulin levels.

Topics PubMed links to this paper include Blood Pressure, Endocrine Glands, Glucose Intolerance, Glucose Tolerance Test, Glycated Hemoglobin, Human Growth Hormone and Infant, Small for Gestational Age.

What This Means in Plain Language

The paper is a randomized, double-blind and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 79 children.

The publication is from 2004 (Journal of pediatric endocrinology & metabolism : JPEM), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.